What they do
Atomwise developed AtomNet, a deep learning neural network that predicts how molecules will interact with target proteins. The technology helps academic institutions and pharmaceutical firms identify promising drug compounds out of millions of virtual candidate molecules.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2012
- Total funding
- $174M raised
Notable investors: Bessemer Venture Partners, B Capital Group, DFJ Growth, Tencent Holdings.